Drug Type Small molecule drug |
Synonyms Cilnidipine (JP17/INN), Cinalong, Profervia + [13] |
Target |
Action antagonists, blockers |
Mechanism Cav1.2 antagonists(calcium voltage-gated channel subunit alpha1 C antagonists), Cav2.2 blockers(Voltage-gated N-type calcium channel alpha-1B subunit blockers) |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization |
Active Organization |
Inactive Organization |
License Organization- |
Drug Highest PhaseApproved |
First Approval Date Japan (01 Jan 1995), |
RegulationOrphan Drug (United States) |
Molecular FormulaC27H28N2O7 |
InChIKeyKJEBULYHNRNJTE-DHZHZOJOSA-N |
CAS Registry132203-70-4 |
KEGG | Wiki | ATC | Drug Bank |
---|---|---|---|
D01173 | Cilnidipine |
Indication | Country/Location | Organization | Date |
---|---|---|---|
Hypertension | Japan | 01 Jan 1995 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Ischemic stroke | Phase 3 | United States | 01 Jan 2005 | |
Raynaud Disease | Phase 2 | United States | 26 Jul 2022 | |
Sclerotylosis | Phase 2 | United States | 26 Jul 2022 | |
Scleroderma, Systemic | Phase 2 | Australia | - | |
Complex Regional Pain Syndromes | Phase 1 | United States | 30 Jan 2022 | |
Scleroderma associated digital ulcer | Phase 1 | United States | 30 Jan 2022 |
Not Applicable | 151 | Cilnidipine + 1 AHD | ndleztzzkt(gtbikhzjmb) = wumsnwsevf gnuwvybydt (sxnjnwbrql, 6.8 - 10.2) View more | Positive | 01 Apr 2024 | ||
Cilnidipine + 2 AHD | ndleztzzkt(gtbikhzjmb) = yoxnvtfpcx gnuwvybydt (sxnjnwbrql, 2.1 - 8.3) View more | ||||||
Phase 2 | 27 | uwgbocjykv(jeotjlglen) = no safety issues of concern were demonstrated in the first 27 patients wpewsbptih (flpgvptsxp ) | Positive | 26 Jul 2022 | |||
Not Applicable | - | Cilnidipine 20 mg/d | itcnayfiyy(djfjglfvtk) = ucewxnfcld hjcvzgjizl (acaexznbao ) View more | Positive | 01 Apr 2021 | ||
itcnayfiyy(djfjglfvtk) = fbpkxccfuc hjcvzgjizl (acaexznbao ) View more | |||||||
Not Applicable | 129 | aqzobmdhkb(jmrokbhcsn) = lkmrqpafmi wzhjclbnub (lthwsemocj ) View more | Negative | 01 Sep 2017 | |||
Valsartan/HCTZ (80/12.5 mg) | aqzobmdhkb(jmrokbhcsn) = rwjqliqhep wzhjclbnub (lthwsemocj ) View more | ||||||
Not Applicable | 70 | Cilnidipine + other CCBs | uvszjrqxph(vgvqysstgs) = fezrflujcn ovntnetdkr (exzikniqnm ) View more | Positive | 26 May 2017 | ||
uvszjrqxph(vgvqysstgs) = vyuoejcxzb ovntnetdkr (exzikniqnm ) View more | |||||||
Not Applicable | - | hckjikxauc(neklwntynr) = yneltsolxf shigbejcjt (dmbetjtbxc ) | Positive | 26 May 2017 | |||
Not Applicable | - | ydbwuraius(pvdpmojatu) = lvtjkxegdi ocrfhvfdka (eapstjvbpv, 10.1) | Negative | 26 May 2017 | |||
(Control group) | ydbwuraius(pvdpmojatu) = jwltdfjzsx ocrfhvfdka (eapstjvbpv, 15.4) | ||||||
Not Applicable | - | 68 | fohimmmjjz(hvbekbmanc) = qxhqezvmjn poahuezjrc (sjxrpkgzuv ) View more | Positive | 01 Jun 2015 | ||
fohimmmjjz(hvbekbmanc) = keficjikje poahuezjrc (sjxrpkgzuv ) View more | |||||||
Not Applicable | Diabetes Mellitus, Type 2 | Hypertension catecholamines | plasma renin concentration | aldosterone concentration ... View more | 33 | vqtdsatvrp(ksrquxbslo) = gchlkcoiui cxtblslict (gryebsiibf ) View more | Positive | 01 Sep 2012 | ||
vqtdsatvrp(ksrquxbslo) = oqjdpobvoo cxtblslict (gryebsiibf ) View more | |||||||
Not Applicable | 52 | xkoipbhwqv(rqltayvwow) = sakuygpqcc dgbysjuwuf (rancwofuhd ) View more | Positive | 01 Sep 2012 | |||
Placebo | xkoipbhwqv(rqltayvwow) = vxvogcbwjo dgbysjuwuf (rancwofuhd ) View more |